ASND · Ascendis Pharma A/S Ordinary Share
Ascendis Pharma A/S (ASND)
What's happening
- ASND is up 1.92% today, trading at $238.83. — Live quote
- Volume today (54,538) is well below its 3-month average of 737,640. (Finnhub fundamentals)
- Reports earnings on 2026-11-09 (after market close), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $0.72 actual vs. $1.41 estimated (-48.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (28 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 114.7% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 70.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is +19.1%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-28; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ASND
No accessible free API for these — links go to the source directly.
Financials
Institutional holders
SEC Form 13F filers holding ASND as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10,281,496 | $2.74B | 16.96% | +0.0% | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 6,754,846 | $1.8M | 11.15% | +9.6% | 2026-08-14 |
| Avoro Capital Advisors LLC | 5,111,111 | $1.36B | 8.43% | +0.0% | 2026-08-14 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4,798,267 | $1.28B | 7.92% | +0.0% | 2026-08-12 |
| Jupiter Topco LLC | 3,648,772 | $973.4M | 6.02% | +0.0% | 2026-08-14 |
| FMR LLC | 3,545,575 | $945.7M | 5.85% | +0.0% | 2026-08-13 |
| Artisan Partners Limited Partnership | 2,634,024 | $702.5M | 4.35% | +0.0% | 2026-08-13 |
| BlackRock, Inc. | 2,211,833 | $589.9M | 3.65% | +0.0% | 2026-08-07 |
| Capital International Investors | 1,988,614 | $530.4M | 3.28% | +0.0% | 2026-08-07 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,875,301 | $500.1M | 3.09% | +0.0% | 2026-08-03 |
| Franklin Templeton Inc | 1,862,503 | $496.8M | 3.07% | +0.0% | 2026-08-04 |
| WELLINGTON MANAGEMENT GROUP LLP | 1,548,636 | $413.1M | 2.56% | +0.0% | 2026-08-14 |
| AMERICAN CENTURY COMPANIES INC | 1,400,575 | $373.6M | 2.31% | +0.0% | 2026-08-12 |
| PERCEPTIVE ADVISORS LLC | 1,163,721 | $310.4M | 1.92% | +0.0% | 2026-08-14 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,122,529 | $299.4K | 1.85% | -26.6% | 2026-08-14 |
| Capital World Investors | 906,081 | $241.7M | 1.50% | +0.0% | 2026-08-07 |
| Principal Financial Group Inc | 873,502 | $233.0M | 1.44% | +0.0% | 2026-07-29 |
| Polar Capital Holdings Plc | 616,908 | $164.5M | 1.02% | +0.0% | 2026-08-14 |
| Goldman Sachs Group Inc | 559,534 | $149.2M | 0.92% | +0.0% | 2026-08-14 |
| Morgan Stanley | 544,393 | $145.2M | 0.90% | +0.0% | 2026-08-11 |
| State Street Corp | 513,969 | $137.1M | 0.85% | +488.5% | 2026-08-07 |
| Invesco Ltd. | 414,196 | $110.5M | 0.68% | +0.0% | 2026-08-13 |
| GEODE CAPITAL MANAGEMENT, LLC | 403,151 | $107.5M | 0.67% | +0.0% | 2026-08-12 |
| UBS Group AG | 401,881 | $107.2M | 0.66% | +0.0% | 2026-08-13 |
| ALLIANCEBERNSTEIN L.P. | 399,292 | $106.5M | 0.66% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:46 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-28 | 4 | 2026-04-14 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-02 | View on SEC.gov → |
| 2026-06-01 | 4 | 2026-05-29 | View on SEC.gov → |
| 2026-06-01 | 4 | 2026-05-29 | View on SEC.gov → |
| 2026-05-27 | 4 | 2026-05-26 | View on SEC.gov → |
| 2026-05-12 | 4 | 2026-05-11 | View on SEC.gov → |
Recent news
Headlines about ASND (Ascendis Pharma A/S Ordinary Share). Links open the publisher — we don’t host full articles.
-
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market
Yahoo · 2026-10-21 -
(ASND) Risk Channels and Responsive Allocation
Stock Traders Daily · 2026-10-20 -
RBC Capital names top healthcare stocks as sector upgraded to overweight
Yahoo · 2026-10-20 -
Ascendis Pharma (ASND) Gets EU Panel Backing, Is The Stock Still Cheap?
Simply Wall Street · 2026-10-19 -
ASND: Ascendis Pharma Latest Stock Price, Analysis, News and Trading Ideas
Stocktwits · 2026-10-18 -
ASND Nov 2026 180.000 call (ASND261120C00180000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
Yahoo · 2026-10-16 -
EU advisers weigh in on once-weekly TransCon CNP for children at Ascendis Pharma (ASND)
Stock Titan · 2026-10-16
No headlines in this category right now — try “All”.